Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib

被引：1
|
作者：
Mok, T. S. K. [1 ]
Liu, G. [2 ]
Nyaw, S. F. [3 ]
Curcio, H. [4 ]
Cortot, A. [5 ]
Kam, T. Y. [6 ]
Descourt, R. [7 ]
Chik, Y. K. [8 ]
Cheema, P. K. [9 ]
Gwinnutt, J. M. [10 ]
Churchill, E. N. [11 ]
Nyborn, J. [12 ]
Curran, E. [13 ]
Yin, Y. [14 ]
Chong, K. [15 ]
Tanaka-Chambers, Y. [16 ]
Kretz, J. [17 ]
Cadranel, J. [18 ,19 ]
机构：
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Princess Margaret Canc Ctr, Ontario Canc Inst, Med Oncol, Toronto, ON, Canada
[3] Tuen Mun Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[4] Ctr Francois Baclesse, Oncol Dept, Caen, France
[5] CHRU Lille, Dept Thorac Oncol, Lille, France
[6] Pamela Youde Nethersole Eastern Hosp Main Block, Dept Clin Oncol, Hong Kong, Peoples R China
[7] CHU Brest, Oncol Dept, Hop Morvan, Brest, France
[8] Queen Elizabeth Hosp QEH, Dept Clin Oncol, Hong Kong, Peoples R China
[9] Univ Toronto, William Osler Hlth Syst, Oncol, Brampton, ON, Canada
[10] IQVIA, Global Epidemiol, Reading, Berks, England
[11] Takeda Pharmaceut USA Inc, Global Med Affairs Oncol, Lexington, MA USA
[12] Takeda Dev Ctr Amer Inc, Global Med Affairs Oncol, Cambridge, MA USA
[13] Takeda Dev Ctr Amer Inc, Global Evidence & Outcome Res, Lexington, MA USA
[14] Takeda Dev Ctr Amer Inc, Observat Res Analyt, Lexington, MA USA
[15] Takeda Dev Ctr Amer Inc, Clin Data Management, Cambridge, MA USA
[16] Takeda Pharmaceut, Stat & Quantitat Sci, Cambridge, MA USA
[17] Takeda Pharmaceut Int AG, Dept Thorac Oncol, Glattpark Opfikon, Zurich, Switzerland
[18] Hop Tenon, AP HP, Pulmonol & Thorac Oncol Dept, Paris, France
[19] Sorbonne Univ Paris, Paris, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.663
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
585P
引用
收藏
页码：S1698 / S1699
页数：2
相关论文
共 50 条
  • [31] Real-world frequency of non-small cell lung cancer with ERBB2 exon 20 insertion (Exon20ins) mutations by site of insertion.
    Yang, Li
    Huang, Tanxiao
    Qu, Yuan
    Wang, Qichen
    Teng, Jiaman
    Yang, Bo
    Chen, Shifu
    Kong, Feng-Ming Spring
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy
    Kim, Tae Min
    Girard, Nicolas
    Low, Grace Kah Mun
    Zhuo, Jianmin
    Yu, Dae Young
    Yang, Yishen
    Murota, Maiko
    Lim, Cindy Thiow Koon
    Kleinman, Nora J.
    Cho, Byoung Chul
    ACTA ONCOLOGICA, 2023, : 1689 - 1697
  • [33] EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study
    Yang, Guangjian
    Li, Jun
    Xu, Haiyan
    Yang, Yaning
    Yang, Lu
    Xu, Fei
    Xia, Bing
    Zhu, Viola W.
    Nagasaka, Misako
    Yang, Yan
    Li, Yapin
    Qiu, Weini
    Ying, Jianming
    Oug, Sai-Hong Ignatius
    Wang, Yan
    LUNG CANCER, 2020, 145 : 186 - 194
  • [34] Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer
    Gonzalvez, Francois
    Vincent, Sylvie
    Baker, Theresa E.
    Gould, Alexandra E.
    Li, Shuai
    Wardwell, Scott D.
    Nadworny, Sara
    Ning, Yaoyu
    Zhang, Sen
    Huang, Wei-Sheng
    Hu, Yongbo
    Li, Feng
    Greenfield, Matthew T.
    Zech, Stephan G.
    Das, Biplab
    Narasimhan, Narayana, I
    Clackson, Tim
    Dalgarno, David
    Shakespeare, William C.
    Fitzgerald, Michael
    Chouitar, Johara
    Griffin, Robert J.
    Liu, Shengwu
    Wong, Kwok-Kin
    Zhu, Xiaotian
    Rivera, Victor M.
    CANCER DISCOVERY, 2021, 11 (07) : 1672 - 1687
  • [35] Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations
    Chen, Chi-Han
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Hsu, Ping-Chih
    Wu, Chiao-En
    ANTICANCER RESEARCH, 2022, 42 (04) : 2145 - 2157
  • [36] Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.
    Ou, Sai-Hong Ignatius
    Lin, Huamao Mark
    Hong, Jin-Liern
    Yin, Yu
    Jin, Shu
    Lin, Jianchang
    Mehta, Minal
    Nguyen, Danny
    Neal, Joel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
    Yoh, Kiyotaka
    Azuma, Koichi
    Hayashi, Hidetoshi
    Nishio, Makoto
    Chikamori, Kenichi
    Ichihara, Eiki
    Watanabe, Yasutaka
    Asato, Takayuki
    Kitagawa, Tadayuki
    Fram, Robert J.
    Ohe, Yuichiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (10) : 1461 - 1474
  • [38] Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
    Li, Kelly
    Bosdet, Ian
    Yip, Stephen
    Ho, Cheryl
    Laskin, Janessa
    Melosky, Barbara
    Wang, Ying
    Sun, Sophie
    CURRENT ONCOLOGY, 2023, 30 (08) : 7099 - 7111
  • [39] Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations
    Winfree, Katherine B.
    Molife, Cliff
    Peterson, Patrick M.
    Chen, Yongmei
    Visseren-Grul, Carla M.
    Leusch, Mark S.
    Beyrer, Julie
    Dimou, Anastasios
    FUTURE ONCOLOGY, 2021, 17 (22) : 2867 - 2881
  • [40] Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations
    Li, Jiaqi
    Xie, Mengqing
    Zhao, Ruiying
    Qiang, Huiping
    Chang, Qing
    Qian, Jialin
    Lu, Haijiao
    Shen, Yinchen
    Han, Yuchen
    Su, Chunxia
    Chu, Tianqing
    FRONTIERS IN ONCOLOGY, 2024, 14
12345